December was profitable for short sellers in the cannabis sector, says a new market report.

According to a document from S3 Partners, a financial technology and analytics firm, cannabis shorts made US$431.9 million during December, with a direct increase in short interest and shares shorted for one particular stock.

Aphria (NYSE:APHA,TSX:APHA) was the only stock to see both its short interest and the amount of shares shorted increase during the reviewed period, S3 Partners said.

“Aphria short sellers were actively shorting into its price decline, more than tripling the size of their short bets since the beginning of November,” wrote Ihor Dusaniwsky, managing director of predictive analytics with S3 Partners.

Aphria faced a 72-percent increase in amount of shares shorted for the period. Meanwhile, short interest in the stock rose from US$131 million at the start of December to US$222 million by last Friday (December 28).

Shares of the Canadian licensed producer have been volatile after uncertainty from a short seller report questioning its acquisitions in Latin America and the characters associated with those purchases.

Additionally, last Thursday (December 27) Aphria received a takeover bid from Green Growth Brands (CSE:GGB). The Columbus, Ohio-based multi-state operator made an offer to combine the two companies’ operations across the US, Canada and globally.

The report indicates that a total decline in short exposure for the cannabis space seen in December wasn’t due to short sellers covering their positions, but instead because of an overall decline in share prices across the sector.

Upcoming landscape for cannabis short sellers

In the S3 Partners report, Dusaniwsky projects the uptick in mergers and acquisitions (M&A) within the cannabis space could lead to an “increase short covering boosting stock price performance.”

“If stocks continue their recent upward trend, shorts may look to cover some of their exposure and realize their profits before they disappear in a puff of smoke,” he states.

S3 Partners indicates a boom in the US cannabis market alongside growing efforts for legalization in Canada and the entrance of the hemp market will lead to more takeovers in the space.

Dena Jalbert, founder and CEO of Align Business Advisory Services, previously told the Investing News Network (INN) that she also expects an uptick in M&A for the cannabis industry.

Short selling in the cannabis space has become popular with investors evaluating the volatile sector.

Charles Taerk, president and CEO of Faircourt Asset Management, explained to INN that short sellers have gravitated towards cannabis since they look for newer sectors with growth and “a perceived amount of volatility” to stake positions.

During a two-day period of weakness in October following Canadian legalization of recreational products, short sellers made gains of US$450 million.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Green Growth Brands is a client of the Investing News Network. This article is not paid-for content.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less